Latest Cash Runway News

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

H2G Limited has received a $774,632.77 R&D tax incentive refund, reinforcing its cash reserves and supporting its renewable energy strategy through 2027. The company plans to update shareholders on progress in its upcoming quarterly report.

Paradigm Biopharmaceuticals has secured US$3 million in its latest tranche under a US$27 million convertible note facility, bolstering funding for its global Phase 3 trial of injectable pentosan polysulfate sodium in knee osteoarthritis.

Recce Pharmaceuticals secured A$4 million through an institutional placement and launched a Share Purchase Plan to raise up to an additional A$4 million, bolstering funds for commercial licensing and ongoing clinical programs.

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Syntara Limited offers existing shareholders a discounted share purchase plan to raise about $2 million, following a recent $8 million institutional placement to fund clinical trials and licensing.

Novo Resources narrowed its Q1 2026 net loss to CAD 685K, boosted cash to CAD 10.6M following a $5.9M placement, and outlined aggressive gold and antimony drilling campaigns in Australia.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Pacific Edge is raising NZ$24 million to shore up its finances and support a crucial Medicare re-coverage bid following a steep revenue drop after losing Medicare reimbursement for its bladder cancer test. The company eyes a draft Medicare policy by September 2026 as a potential turning point.

NT Minerals has launched a pro-rata non-renounceable entitlement offer aiming to raise up to $968,722 at $0.002 per share, providing shareholders a chance to subscribe for two shares for every five held. The offer opened on 5 May 2026 and closes on 26 May 2026, with electronic access to prospectus documents and a focus on reducing paper usage.